• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.

作者信息

Kontoghiorghes G J, Bartlett A N, Hoffbrand A V

机构信息

Department of Haematology, Royal Free Hospital Medical School, London, UK.

出版信息

Prog Clin Biol Res. 1989;309:107-14.

PMID:2780745
Abstract
摘要

相似文献

1
Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮及其他α - 酮羟基吡啶用于人体有效口服铁螯合疗法的前景
Prog Clin Biol Res. 1989;309:107-14.
2
Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.1-2，二甲基-3-羟基吡啶-4-酮（L1）作为口服铁螯合剂用于重度β地中海贫血铁过载患者的疗效和安全性。
J Assoc Physicians India. 1991 Sep;39(9):669-72.
3
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.口服螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮对β地中海贫血中铁的有效螯合作用
Br Med J (Clin Res Ed). 1987 Dec 12;295(6612):1509-12. doi: 10.1136/bmj.295.6612.1509.
4
Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.地中海贫血患者口服螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮的研究。
Semin Hematol. 1990 Apr;27(2):101-4.
5
Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.在铁过载的地中海贫血患者中使用1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）进行口服铁螯合治疗。
Bone Marrow Transplant. 1993;12 Suppl 1:9-11.
6
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.去铁酮对转铁蛋白和非转铁蛋白结合铁的铁动员作用。对地中海贫血、慢性病贫血、癌症及其他病症治疗的意义。
Hemoglobin. 2006;30(2):183-200. doi: 10.1080/03630260600642450.
7
Iron chelation.
J Assoc Physicians India. 1991 Sep;39(9):665-6.
8
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.输血依赖型地中海贫血患者不遵守铁螯合疗法的后果及成本：一项文献综述
Transfusion. 2007 Oct;47(10):1919-29. doi: 10.1111/j.1537-2995.2007.01416.x.
9
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）的长期试验。I. 铁螯合与代谢研究。
Br J Haematol. 1990 Oct;76(2):295-300. doi: 10.1111/j.1365-2141.1990.tb07887.x.
10
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.地中海贫血及其他病症未来的螯合单药治疗和联合治疗策略。去铁酮、去铁胺、ICL670、GT56-252、L1NAll和淀粉去铁胺聚合物的比较
Hemoglobin. 2006;30(2):329-47. doi: 10.1080/03630260600642674.

引用本文的文献

1
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.去铁酮治疗地中海贫血及其他病症铁过载的获益与风险：与去铁胺的流行病学及治疗学方面比较
Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003.
2
Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).口服铁螯合作用：一篇特别强调印度关于去铁酮（L1）研究工作的综述。
Indian J Pediatr. 1993 Jul-Aug;60(4):509-16. doi: 10.1007/BF02751427.
3
Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
地中海贫血及其他疾病中口服铁螯合疗法的现状与未来前景
Indian J Pediatr. 1993 Jul-Aug;60(4):485-507. doi: 10.1007/BF02751425.